Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

Description

Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

Conditions

Myopia

Talk to us

Study Overview

On this page

Study Details

Study overview

Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control: a Randomized Controlled Trial

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

Condition
Myopia
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Provision of consent
  • 2. Age: ≥8 and ≤13 years at enrollment
  • 3. Myopia: Spherical equivalent refractions (SERs) under cycloplegia: -1.00 to -5.00 diopters (D)
  • 4. Astigmatism of 2.50 D or less
  • 5. Anisometropia of 1.50 D or less
  • 6. Corrected monocular logMAR visual acuity (VA): 1.0 or better
  • 7. Consent to participate in random allocation of grouping
  • 8. Fluent in English
  • 9. Willing and able to participate in all required activities of the study
  • 10. Race/ethnicity is either African, Hispanic, or Caucasian.
  • 1. Strabismus and binocular vision abnormalities in either eye
  • 2. Ocular abnormalities in either eye or other systemic abnormalities that affect participate in all required activities of the study.
  • 3. Prior treatment of myopia control in either eye, including but not limited to drugs, orthokeratology, progressive addition lenses, bifocal lenses, etc.
  • 4. Other reasons, including but not limited to severe physical and cognitive disability, that the physician may consider inappropriate for enrollment
  • 5. Noncompliance with treatment
  • 6. Children whose parents do not sign informed consent

Ages Eligible for Study

8 Years to 13 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, San Francisco,

Julius Oatts, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2025-07-14